• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4616374)   Today's Articles (3144)   Subscriber (49395)
For: Ikeda H, Suzuki M, Okuse C, Yamada N, Okamoto M, Kobayashi M, Nagase Y, Takahashi H, Matsunaga K, Matsumoto N, Itoh F, Yotsuyanagi H, Koitabashi Y, Yasuda K, Iino S. Short-term prolongation of pegylated interferon and ribavirin therapy for genotype 1b chronic hepatitis C patients with early viral response. Hepatol Res 2009;39:753-9. [PMID: 19467024 DOI: 10.1111/j.1872-034x.2009.00523.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Number Cited by Other Article(s)
1
Deng L, Wang XH. Progress in antiviral treatment of chronic hepatitis C virus genotype 1 infection. Shijie Huaren Xiaohua Zazhi 2015;23:4368-4375. [DOI: 10.11569/wcjd.v23.i27.4368] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]  Open
2
Noguchi Y, Kurokawa MS, Okuse C, Matsumoto N, Nagai K, Sato T, Arito M, Suematsu N, Okamoto K, Suzuki M, Itoh F, Kato T. Serum peptides, represented by complement 3f des-arginine, are useful for prediction of the response to pegylated interferon-α plus ribavirin in patients with chronic hepatitis C. Hepatol Res 2013;43:743-56. [PMID: 23216931 DOI: 10.1111/hepr.12018] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/24/2012] [Revised: 10/08/2012] [Accepted: 10/31/2012] [Indexed: 02/06/2023]
3
Andriulli A, Iacobellis A, Valvano MR, Spirito F, Ippolito A, Bossa F, Terracciano F, Fontana R, Niro G. Estimates of HCV-1 patients attaining RVR following dual therapy with peg-interferon and ribavirin. Dig Dis Sci 2013. [PMID: 23187978 DOI: 10.1007/s10620-012-2484-x] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
4
Nishimura T, Yamaguchi K, Hashimoto H, Niimi T, Yokomizo C, Fujii H, Minami M, Sakamoto M, Ohnish N, Nagao Y, Okita M, Umemura A, Shima T, Okanoue T, Itoh Y. Treatment extension may benefit female genotype 1 chronic hepatitis C patients with complete early virological response to peginterferon-alpha-2b and ribavirin combination therapy. Hepatol Res 2012;42:966-73. [PMID: 22548706 DOI: 10.1111/j.1872-034x.2012.01016.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
5
Kurosaki M, Sakamoto N, Iwasaki M, Sakamoto M, Suzuki Y, Hiramatsu N, Sugauchi F, Tamori A, Nakagawa M, Izumi N. Sequences in the interferon sensitivity-determining region and core region of hepatitis C virus impact pretreatment prediction of response to PEG-interferon plus ribavirin: data mining analysis. J Med Virol 2011;83:445-52. [PMID: 21264865 DOI: 10.1002/jmv.22005] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
6
Optimal Duration of Treatment for HCV Genotype 1 Infection in Slow Responders: A Meta-Analysis. HEPATITIS MONTHLY 2011. [DOI: 10.5812/kowsar.1735143x.2187] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/13/2023]
7
Honda A, Matsuzaki Y. Cholesterol and chronic hepatitis C virus infection. Hepatol Res 2011;41:697-710. [PMID: 21682830 DOI: 10.1111/j.1872-034x.2011.00838.x] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
8
Parikh M, Singh A, Sood G. Extended treatment duration for treatment naïve chronic hepatitis C genotype 1 late viral responders: a meta-analysis comparing 48 weeks vs 72 weeks of pegylated interferon and ribavirin. J Viral Hepat 2011;18:e99-103. [PMID: 20950407 DOI: 10.1111/j.1365-2893.2010.01374.x] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
9
Farnik H, Lange CM, Sarrazin C, Kronenberger B, Zeuzem S, Herrmann E. Meta-analysis shows extended therapy improves response of patients with chronic hepatitis C virus genotype 1 infection. Clin Gastroenterol Hepatol 2010;8:884-90. [PMID: 20601130 DOI: 10.1016/j.cgh.2010.06.019] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/17/2010] [Revised: 06/17/2010] [Accepted: 06/18/2010] [Indexed: 02/07/2023]
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA